000180069 001__ 180069
000180069 005__ 20240229145604.0
000180069 0247_ $$2doi$$a10.1093/neuonc/noac138
000180069 0247_ $$2pmid$$apmid:35609569
000180069 0247_ $$2ISSN$$a1522-8517
000180069 0247_ $$2ISSN$$a1523-5866
000180069 0247_ $$2altmetric$$aaltmetric:128901033
000180069 037__ $$aDKFZ-2022-01068
000180069 041__ $$aEnglish
000180069 082__ $$a610
000180069 1001_ $$0P:(DE-He78)1cab354af0aff62f1b8d569477b4be4c$$aFriedrich, Mirco$$b0$$eFirst author$$udkfz
000180069 245__ $$aDysfunctional dendritic cells limit antigen-specific T cell response in glioma.
000180069 260__ $$aOxford$$bOxford Univ. Press$$c2023
000180069 3367_ $$2DRIVER$$aarticle
000180069 3367_ $$2DataCite$$aOutput Types/Journal article
000180069 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1698998885_23211
000180069 3367_ $$2BibTeX$$aARTICLE
000180069 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180069 3367_ $$00$$2EndNote$$aJournal Article
000180069 500__ $$a#EA:D170#LA:D170#  / 2023 Feb 14;25(2):263-276 / HI-TRON
000180069 520__ $$aDendritic cells (DC), the most potent professional antigen presenting cells capable of effective cross-presentation, have been demonstrated to license T helper cells to induce anti-tumor immunity in solid tumors. Specific DC subtypes are recruited to the injured brain by microglial chemokines, locally adapting to distinct transcriptional profiles. In isocitrate dehydrogenase type 1 (IDH) mutant gliomas, monocyte-derived macrophages have recently been shown to display an attenuated intratumoral antigen presentation capacity as consequence of the local accumulation of the oncometabolite R-2-hydroxyglutarate. The functionality and the contribution of DC to the IDH-mutant tumor microenvironment (TME) remains unclear.Frequencies and intratumoral phenotypes of human DC in IDH-wildtype and -mutant high-grade gliomas are comparatively assessed by transcriptomic and proteomic profiling. DC functionality is investigated in experimental murine glioblastomas expressing the model antigen ovalbumin. Single-cell sequencing-based pseudotime analyses and spectral flow cytometric analyses are used to profile DC states longitudinally.DC are present in primary and recurrent high-grade gliomas and interact with other immune cell types within the TME. In murine glioblastomas, we find an IDH-status-associated major histocompatibility class I-restricted cross-presentation of tumor antigens by DC specifically in the tumor but not in meninges or secondary lymphoid organs of tumor-bearing animals. In single-cell sequencing-based pseudotime and longitudinal spectral flow cytometric analyses, we demonstrate an IDH-status-dependent differential, exclusively microenvironmental education of DC.Glioma-associated DCs are relevantly abundant in human IDH wildtype and mutant tumors. Glioma IDH mutations result in specifically educated, dysfunctional DCs via paracrine reprogramming of infiltrating monocytes, providing the basis for combinatorial immunotherapy concepts against IDH mutant gliomas.
000180069 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000180069 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000180069 650_7 $$2Other$$aIDH mutation
000180069 650_7 $$2Other$$aR-2-HG
000180069 650_7 $$2Other$$acDC1
000180069 650_7 $$2Other$$acDC2
000180069 650_7 $$2Other$$adendritic cell
000180069 650_7 $$2Other$$aglioblastoma
000180069 650_7 $$2Other$$aglioma microenvironment
000180069 7001_ $$0P:(DE-He78)212c3f360575b681240dd71d858c08e1$$aHahn, Markus$$b1$$udkfz
000180069 7001_ $$0P:(DE-He78)513be409835c710d4fe381543a45b410$$aMichel, Julius$$b2$$udkfz
000180069 7001_ $$aSankowski, Roman$$b3
000180069 7001_ $$0P:(DE-He78)bed62b0b74cf1048663fbefeb4b5d7bc$$aKilian, Michael$$b4$$udkfz
000180069 7001_ $$0P:(DE-He78)fad274ed48f42202270f60e22b0bcdd1$$aKehl, Niklas$$b5$$udkfz
000180069 7001_ $$0P:(DE-He78)b676990c2f64e3295740d42e356fb053$$aGünter, Manina$$b6$$udkfz
000180069 7001_ $$0P:(DE-He78)e681100c540b628a2bdbd48772b4fb50$$aBunse, Theresa$$b7$$udkfz
000180069 7001_ $$0P:(DE-He78)f2efee17b6ca2f790176a2c036912536$$aPusch, Stefan$$b8$$udkfz
000180069 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b9$$udkfz
000180069 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b10$$udkfz
000180069 7001_ $$0P:(DE-He78)d3dbba28fe1239effd15962787cbc363$$aAutenrieth, Stella E$$b11$$udkfz
000180069 7001_ $$00000-0002-0349-1955$$aPrinz, Marco$$b12
000180069 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b13$$udkfz
000180069 7001_ $$0P:(DE-He78)e579130c57e8c686ed1c2dedfa595985$$aBunse, Lukas$$b14$$eLast author$$udkfz
000180069 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noac138$$gp. noac138$$n2$$p263-276$$tNeuro-Oncology$$v25$$x1522-8517$$y2023
000180069 909CO $$ooai:inrepo02.dkfz.de:180069$$pVDB
000180069 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1cab354af0aff62f1b8d569477b4be4c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000180069 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)212c3f360575b681240dd71d858c08e1$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000180069 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)513be409835c710d4fe381543a45b410$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000180069 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bed62b0b74cf1048663fbefeb4b5d7bc$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000180069 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fad274ed48f42202270f60e22b0bcdd1$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000180069 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b676990c2f64e3295740d42e356fb053$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000180069 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e681100c540b628a2bdbd48772b4fb50$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000180069 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f2efee17b6ca2f790176a2c036912536$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000180069 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000180069 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000180069 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d3dbba28fe1239effd15962787cbc363$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000180069 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000180069 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e579130c57e8c686ed1c2dedfa595985$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000180069 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000180069 9141_ $$y2022
000180069 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000180069 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000180069 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000180069 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000180069 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000180069 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000180069 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000180069 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000180069 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000180069 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000180069 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000180069 9202_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x0
000180069 9201_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x0
000180069 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000180069 9201_ $$0I:(DE-He78)F171-20160331$$kF171$$lDentritische Zellen bei Infektionen und Krebs$$x2
000180069 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x3
000180069 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x4
000180069 9200_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x0
000180069 980__ $$ajournal
000180069 980__ $$aVDB
000180069 980__ $$aI:(DE-He78)D170-20160331
000180069 980__ $$aI:(DE-He78)HD01-20160331
000180069 980__ $$aI:(DE-He78)F171-20160331
000180069 980__ $$aI:(DE-He78)B300-20160331
000180069 980__ $$aI:(DE-He78)B320-20160331
000180069 980__ $$aUNRESTRICTED